• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Sun Pharmaceutical Industries Ltd.
    08 Jul 2024
    US FDA Classification
    1616.60
    0.43%
    Open to inorganic opportunities in specialty drugs, says Sun Pharma
    Business Standard
    Sun Pharma has net cash position of $2.4 bn at end of FY24; 6 new specialty products in R&D pipeline
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Cipla Ltd.
    05 Jul 2024
    1574.60
    0.88%
    bl exclusive: Cipla is now completely professionalised, says MD and Global CEO Umang Vohra
    Business Line
    The drugmaker plans to increase its innovative revenues through its contribution in newer and emerging therapies
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    logo
    Shilpa Medicare Ltd.
    05 Jul 2024
    827.60
    -1.08%
    This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24
    Business Standard
    Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading above its 200 day SMA of 786.3
    logo
    Shilpa Medicare Ltd.
    05 Jul 2024
    827.60
    -1.08%
    Stock Of The Day: Shilpa Medicare Rallies After Order For Kidney Disease Treatment Key Levels
    Stock Of The Day: Shilpa Medicare Rallies After Order For Kidney Disease Treatment Key Levels
    NDTV Profit
    Here is all you need to know about the Shilpa Medicare's order win, its impact and future plans.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading above its 200 day SMA of 786.3
    logo
    FDC Ltd.
    05 Jul 2024
    463.35
    -0.33%
    Stock to buy today: FDC (507): BUY
    Business Line
    FDC share price can rise further to 525-530
    Copy LinkShare onShare on Share on Share on
    FDC Ltd. is trading below its 30 day SMA of 471.0
    logo
    Dr. Reddy's Laboratories Ltd.
    04 Jul 2024
    Acquisition
    1316.70
    1.04%
    Dr Reddy's, Sun Pharma Recall Drugs In US Due To Manufacturing Issues
    Dr Reddy's, Sun Pharma Recall Drugs In US Due To Manufacturing Issues
    NDTV Profit
    Dr. Reddy's Laboratories and Sun Pharma are recalling products in the US because of manufacturing issues.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr Reddy's Lab pushes the pedal to touch 1.5 billion patients by FY30
    Business Standard | 04 Jul 2024 1 more
    Dr Reddy's to work closely' with USFDAon biosimilar rituximab to launch it in US
    Business Line | 04 Jul 2024
    logo
    Lupin Ltd.
    04 Jul 2024
    2043.40
    2.79%
    Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook
    Business Standard
    Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. is trading above all available SMAs
    Lupin stock rallies 7%, hits multi-year high on healthy earnings outlook
    Business Standard | 04 Jul 2024 1 more
    Lupin Gets Double Upgrade From Kotak On Robust Earnings Outlook; Shares Gain
    NDTV Profit | 04 Jul 2024
    logo
    Dr. Reddy's Laboratories Ltd.
    04 Jul 2024
    Acquisition
    1316.70
    1.04%
    Dr Reddy's, Sun Pharma recall drugs in US due to production issues: USFDA
    Business Standard
    Dr Reddy's Laboratories and Sun Pharma are recalling products in the US due to manufacturing issues, as per the latest Enforcement Report by the US Food and Drug Administration (USFDA). According to the report, Dr Reddy's Laboratories is recalling drugs to treat insomnia and gout in the American market. New Jersey-based Dr Reddy's Laboratories, Inc., a unit of Hyderabad-based drug major, is recalling 13,752 bottles of Eszopiclone tablets, the USFDA stated. The affected lot has been produced at Dr Reddy's Bachupally plant in Telangana. As per the USFDA, the drug firm is recalling the affected lot due to "Failed Impurities/Degradation Specifications". The company issued the Class III nationwide recall on June 4 this year. As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". Dr Reddy's Laboratories, Inc. is also recalling 20,520 units of Allopurinol tablets in the
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 11 Sep, 2025.
    logo
    AstraZeneca Pharma India Ltd.
    04 Jul 2024
    Show Cause Notice
    9003.50
    -0.75%
    AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai
    Business Standard
    This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    AstraZeneca to invest 250 cr in Chennai
    Business Line | 04 Jul 2024
    logo
    Sun Pharmaceutical Industries Ltd.
    04 Jul 2024
    US FDA Classification
    1616.60
    0.43%
    USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility
    Business Standard
    Sun Pharma failed to adequately clean and maintain equipment used for drug manufacturing at its Dadra-based manufacturing plant, as per the US Food and Drug Administration (USFDA). In a warning letter issued to company's Managing Director Dilip Shanghvi on June 18, the US health regulator stated it inspected the plant in the Union Territory of Dadra and Nagar Haveli and Daman and Diu from December 4-15, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said. The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility, it stated. USFDA further noted that the company's investigations
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd